[go: up one dir, main page]

WO1992000725A1 - Compositions pharmaceutiques liquides de traitement oral presentant une activite anti-inflammatoire - Google Patents

Compositions pharmaceutiques liquides de traitement oral presentant une activite anti-inflammatoire Download PDF

Info

Publication number
WO1992000725A1
WO1992000725A1 PCT/EP1991/001245 EP9101245W WO9200725A1 WO 1992000725 A1 WO1992000725 A1 WO 1992000725A1 EP 9101245 W EP9101245 W EP 9101245W WO 9200725 A1 WO9200725 A1 WO 9200725A1
Authority
WO
WIPO (PCT)
Prior art keywords
compositions according
active ingredient
ketoprofen
cyclodextrins
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1991/001245
Other languages
English (en)
Inventor
Ubaldo Conte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FARCON AG
Original Assignee
FARCON AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FARCON AG filed Critical FARCON AG
Priority to DE1991911791 priority Critical patent/DE491897T1/de
Publication of WO1992000725A1 publication Critical patent/WO1992000725A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Definitions

  • the present invention relates to liquid pharmaceu ⁇ tical compositions for the oral topical treatment, containing non steroidal anti-inflammatory drugs as the active ingredients.
  • Therapeutical treatment of inflammations of the oral cavity such as aspecific odontostomatologic af ⁇ fections, gingivitis, glossitis, stomatitis and the like, is particularly complex and, until the specific pathogenic agent has precisely been determined, treat- ment can be restricted to the use of disinfectants of the general type.
  • Said drugs besides showing negative characteri ⁇ stics (remarkable side-effects) can cause severe and diffused allergy phenomena, so as to compel to immedia- tely interrupt treatment and to take suitable restora ⁇ tion measures.
  • compositions comprising non steroidal anti-inflammatory drugs (FANS) in form of solutions intended for the oral topical tre ⁇ atment (collutories) , allow to obtain very good thera ⁇ Promotionical results without causing sensitization pheno ⁇ mena.
  • FANS non steroidal anti-inflammatory drugs
  • the compositions of the invention are characteri ⁇ zed by the presence of a specific excipient, dimethyl isosorbide, giving them advantageous antiseptic proper ⁇ ties together with an antiplaque action which is parti- cularly desired in this kind of preparations.
  • Anti-in ⁇ flammatory properties of the active ingredients also turn out to be surprisingly enhanced through a synerge- tic interaction with dimethyl isosorbide.
  • compositions of the present invention can con- tain the active ingredient in amounts ranging from 0.001 to 20% by weight, whereas dimethyl isosorbide can be present in amounts ranging from 1 to 40% by weight.
  • compositions of the invention can also contain other excipients and/or coadjuvants, such as surfactants, flavouring and sweetening agents, in order to give the preparation suitable organoleptic characteristics.
  • excipients and/or co ⁇ adjuvants conventionally used for the preparation of collutories are described in "Remington's Pharm. Scien- ces Handbook", Mack Pub. Co., NY.
  • the compositions of the invention will preferably contain natural and/or synthetic sweetening agents such as saccharine, ammo ⁇ nium glycyrrhizinate, cycla ate or, more preferably, not cariogenic carbohydrates such as xylitol and sorbi- tol.
  • non steroidal anti- inflammatory drugs such as ketoprofen, ibuprofen, ibu- profen lysine salt, naproxen, suprofen, diclofenac, al- clofenac, indomethacin, acemethacin, benzidamine, flur- biprofen, piroxicam and the like, can be used as active ingredients, either in the free form or salified, in order to improve the solubility thereof.
  • the active ingredients are present in combination with cyclodextrins or derivatives thereof, for example in form of physical admixtures, inclusion products or co- precipitates.
  • Cyclodextrins or derivatives thereof such as hydroxypropyl beta-cyclodextrins, involve fa ⁇ vourable pharmacokinetic effects and, moreover, are useful to increase solubility and stability, or to im- prove the organoleptic characteristics of the medica ⁇ ment.
  • Cyclodextrin contents can range from 0.5 to 50% by weight of the finished composition, but equimolecular ratios of active ingredient to cyclodextrin are prefe- rably used.
  • cyclodex ⁇ trins (o , ⁇ , -) and the already cited hydroxypropyl ⁇ - cyclodextri ⁇ , dimethylcyclodextrins or other derivati ⁇ ves, possibly in a mixture thereof can also be used.
  • polymers having an adhesive power towards ucosae are used as excipients.
  • examples of said polymers are provided by carboxyvinyl polymers, ethyle e oxide - propylene oxide copolymers, cellulose derivatives such as carboxymethyl cellulose, calcium carboxymethyl cellulose, hydroxy- propylethyl cellulose, hydroxyethyl cellulose, hydroxy ⁇ propyl cellulose, carrageenan, dextrins, natural or synthetic gums and the like.
  • Said excipients, which can be def ned bioadhesive polymers can be present in per ⁇ centages ranging from 0.5 to 30%, preferably from 1 to 5%.
  • excipients allows to obtain sli ⁇ ghtly viscous solutions having adhesiveness towards mu- cosae, so as to achieve a better persistence of the preparation in contact with the area to be treated, thus obtaining a more effective and lasting action.
  • compositions can also contain no dimethyl isosor- bide : said compositions also fall within the scope of the present invention.
  • Each 15 ml ampoule contains: Active ingredient: ketoprofen Excipients:
  • Ketoprofen is dissolved in an ethanol solution containing dimethyl isosorbide and Tween 60, the solu ⁇ tion is heated to 35 C C under stirring, to obtain a clear solution which is added with the other components. After filtration, a clear homogeneous solution (collutory) is obtained.
  • Ketoprofen is added to a ⁇ -cyclodextrin aqueous solution (about 50 ml), which is heated to 30-40 e C for 30 hours. A solution is obtained which is added with dimethyl isosorbide and the other components, then fil ⁇ tered.
  • EXAMPLE 4 Collutory containing ketoprofen, dimethyl isosorbide and bioadhesive polymers (in form of solution) 100 ml of collutory contain (% composition): Active ingredient: ketoprofen 0.05 Excipients:
  • Each 15 ml ampoule contains : Active ingredient: Benzidamine 2 to 20 mg ExciDients: Tween 60 5 mg alpine herb flavor 52,503 T 15 mg dimethyl isosorbide 1500 mg
  • Collutory containing piroxicam (in form of solution) 100 ml of collutory contain (% composition) : Active ingredient:
  • Each 15 ml ampoule contains: Active ingredient: Piroxicam Excipients:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

On décrit des compositions pharmaceutiques liquides pour le traitement topique oral, contenant comme ingrédients actifs des médicaments anti-inflammatoires non stéroïdiens, caractérisées en ce qu'elles renferment de l'isosorbide diméthylique comme vecteur.
PCT/EP1991/001245 1990-07-13 1991-07-04 Compositions pharmaceutiques liquides de traitement oral presentant une activite anti-inflammatoire Ceased WO1992000725A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE1991911791 DE491897T1 (de) 1990-07-13 1991-07-04 Fluessige entzuendungshemmende oral anzuwendende arzneimittel.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT02094490A IT1243342B (it) 1990-07-13 1990-07-13 Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria
IT20944A/90 1990-07-13

Publications (1)

Publication Number Publication Date
WO1992000725A1 true WO1992000725A1 (fr) 1992-01-23

Family

ID=11174427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1991/001245 Ceased WO1992000725A1 (fr) 1990-07-13 1991-07-04 Compositions pharmaceutiques liquides de traitement oral presentant une activite anti-inflammatoire

Country Status (7)

Country Link
EP (1) EP0491897A1 (fr)
AU (1) AU8093591A (fr)
CA (1) CA2066731A1 (fr)
ES (1) ES2034926T1 (fr)
GR (1) GR930300021T1 (fr)
IT (1) IT1243342B (fr)
WO (1) WO1992000725A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025190A1 (fr) * 1992-06-10 1993-12-23 Eastman Kodak Company Nanoparticules de medicaments anti-inflammatoires non steroidiens modifiees en surface
WO1994028936A1 (fr) * 1993-06-08 1994-12-22 Ciba-Geigy Ag Procede de preparation d'une forme galenique orale solide contenant du diclofenac
WO1995007104A1 (fr) * 1993-09-11 1995-03-16 Smithkline Beecham Plc Complexes d'insertion de bêta-cyclodextrine et de flurbiprofene, cetoprofene, et naproxene
WO1995023591A1 (fr) * 1994-03-03 1995-09-08 The Procter & Gamble Company Compositions d'excipient d'administration par voie orale
EP0627915A4 (fr) * 1992-12-04 1996-02-07 Mayor Pharma Lab Inc Composition analgesique pulverisable.
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
WO1997003655A1 (fr) * 1995-07-20 1997-02-06 Pharmacia & Upjohn Company Solution claire et stable d'anti-inflammatoires non steroidiens a integrer dans des gelules de gelatine
US5626837A (en) * 1993-08-12 1997-05-06 Lion Corporation Oral composition
WO1997018802A1 (fr) * 1995-11-22 1997-05-29 The Boots Company Plc Compositions pharmaceutiques contenant du flurbiprofene
US5674854A (en) * 1993-10-08 1997-10-07 Farmarc Nederland Bv Inclusion complex of beta-cyclodextrin and diclofenac, its preparation and use
US5679660A (en) * 1993-12-02 1997-10-21 Farmarc Nederland Bv Pharmaceutical composition comprising diclofenac and cyclodextrin
DE19651055A1 (de) * 1996-12-09 1998-06-10 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Triazinderivaten und Dimethylisosorbid
WO1998052539A1 (fr) * 1997-05-22 1998-11-26 The Boots Company Plc Procede de production de pastilles de flurbiprofene
US6071964A (en) * 1996-03-27 2000-06-06 Hexal Ag Diclofenac/gamma-cyclodextrin inclusion compounds
ES2171110A1 (es) * 2000-03-03 2002-08-16 Aplicaciones Farmacodinamicas Composicion farmaceutica a base de ibuprofeno y procedimiento para su preparacion.
WO2003094905A1 (fr) * 2002-05-10 2003-11-20 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Composition a base de diclofenac pour traitement local de troubles de cavite oropharyngee
WO2005074885A1 (fr) * 2004-02-03 2005-08-18 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
GB2416123B (en) * 2003-04-07 2007-06-06 Jurox Pty Ltd Stable carprofen composition
ES2347754A1 (es) * 2009-04-27 2010-11-03 Laboratorios De Aplicaciones Farmacodinamicas, S.A Suspension oral de lisinato de ibuprofeno.
GB2486567A (en) * 2010-12-15 2012-06-20 Reckitt Benckiser Healthcare Int Ltd Solutions of an NSAID and one or more cyclodextrins
JP2012525359A (ja) * 2009-04-27 2012-10-22 ラボラトリオ デ アプリカシオネス ファルマコディナミカス，エセ．アー． イブプロフェンリシナートの経口投与用の懸濁液
US8580954B2 (en) 2006-03-28 2013-11-12 Hospira, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
WO2019105957A1 (fr) * 2017-11-30 2019-06-06 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Composition liquide stable de kétoprofène, sels et énantiomères de celui-ci

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0215423A2 (fr) * 1985-09-12 1987-03-25 Dolorgiet GmbH & Co. KG Préparations aqueuses résorbables par voie transdermale contenant des dérivés de l'acide arylpropionique et leur procédé de fabrication
EP0284588A1 (fr) * 1987-03-13 1988-09-28 "PHARLYSE", Société Anonyme Préparation pharmaceutique à base d'indométacine
WO1989004179A1 (fr) * 1987-11-03 1989-05-18 Also Laboratori S.A.S. Formulations pharmaceutiques pour administration transcutanee

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0215423A2 (fr) * 1985-09-12 1987-03-25 Dolorgiet GmbH & Co. KG Préparations aqueuses résorbables par voie transdermale contenant des dérivés de l'acide arylpropionique et leur procédé de fabrication
EP0284588A1 (fr) * 1987-03-13 1988-09-28 "PHARLYSE", Société Anonyme Préparation pharmaceutique à base d'indométacine
WO1989004179A1 (fr) * 1987-11-03 1989-05-18 Also Laboratori S.A.S. Formulations pharmaceutiques pour administration transcutanee

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
WO1993025190A1 (fr) * 1992-06-10 1993-12-23 Eastman Kodak Company Nanoparticules de medicaments anti-inflammatoires non steroidiens modifiees en surface
EP0627915A4 (fr) * 1992-12-04 1996-02-07 Mayor Pharma Lab Inc Composition analgesique pulverisable.
WO1994028936A1 (fr) * 1993-06-08 1994-12-22 Ciba-Geigy Ag Procede de preparation d'une forme galenique orale solide contenant du diclofenac
US5702724A (en) * 1993-06-08 1997-12-30 Ciba-Geigy Corporation Process for the preparation of an oral solid dosage form containing diclofenac
US5626837A (en) * 1993-08-12 1997-05-06 Lion Corporation Oral composition
WO1995007104A1 (fr) * 1993-09-11 1995-03-16 Smithkline Beecham Plc Complexes d'insertion de bêta-cyclodextrine et de flurbiprofene, cetoprofene, et naproxene
US5674854A (en) * 1993-10-08 1997-10-07 Farmarc Nederland Bv Inclusion complex of beta-cyclodextrin and diclofenac, its preparation and use
US5679660A (en) * 1993-12-02 1997-10-21 Farmarc Nederland Bv Pharmaceutical composition comprising diclofenac and cyclodextrin
AU702889B2 (en) * 1994-03-03 1999-03-11 Procter & Gamble Company, The Oral vehicle compositions
WO1995023591A1 (fr) * 1994-03-03 1995-09-08 The Procter & Gamble Company Compositions d'excipient d'administration par voie orale
WO1997003655A1 (fr) * 1995-07-20 1997-02-06 Pharmacia & Upjohn Company Solution claire et stable d'anti-inflammatoires non steroidiens a integrer dans des gelules de gelatine
WO1997018802A1 (fr) * 1995-11-22 1997-05-29 The Boots Company Plc Compositions pharmaceutiques contenant du flurbiprofene
US5889057A (en) * 1995-11-22 1999-03-30 The Boots Company Plc Flurbiprofen lozenge for the treatment of sore throat
AU707749B2 (en) * 1995-11-22 1999-07-22 Reckitt Benckiser Healthcare (Uk) Limited Medical Treatment
US6166083A (en) * 1995-11-22 2000-12-26 The Boots Company, Plc Suckable flurbiprofen lozenges for treatment of sore throat
US6071964A (en) * 1996-03-27 2000-06-06 Hexal Ag Diclofenac/gamma-cyclodextrin inclusion compounds
DE19651055B4 (de) * 1996-12-09 2006-03-16 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Triazinderivaten und Dimethylisosorbid und deren Verwendung
DE19651055A1 (de) * 1996-12-09 1998-06-10 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Triazinderivaten und Dimethylisosorbid
WO1998052539A1 (fr) * 1997-05-22 1998-11-26 The Boots Company Plc Procede de production de pastilles de flurbiprofene
US6194003B1 (en) 1997-05-22 2001-02-27 The Boots Company Plc Process for making flurbiprofen lozenges
ES2171110A1 (es) * 2000-03-03 2002-08-16 Aplicaciones Farmacodinamicas Composicion farmaceutica a base de ibuprofeno y procedimiento para su preparacion.
WO2003094905A1 (fr) * 2002-05-10 2003-11-20 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Composition a base de diclofenac pour traitement local de troubles de cavite oropharyngee
CN1303992C (zh) * 2002-05-10 2007-03-14 方济各安吉利克化学联合股份有限公司 用于局部治疗口咽腔疾病的基于双氯芬酸的组合物
GB2416123B (en) * 2003-04-07 2007-06-06 Jurox Pty Ltd Stable carprofen composition
US8846083B2 (en) 2004-02-03 2014-09-30 Philippe Perovitch Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method
WO2005074885A1 (fr) * 2004-02-03 2005-08-18 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
EP1711162B1 (fr) 2004-02-03 2017-11-01 Philippe Perovitch Composition pour l'utilisation dans le traitement local des affections bucco-pharyngées comprenant de l'ibuprofène ou du kétoprofène
RU2388468C2 (ru) * 2004-02-03 2010-05-10 Филипп ПЕРОВИЧ Способ диффузии молекул, не растворимых в водной среде, и композиция для осуществления этого способа
US8946292B2 (en) 2006-03-28 2015-02-03 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
US8580954B2 (en) 2006-03-28 2013-11-12 Hospira, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
JP2012525359A (ja) * 2009-04-27 2012-10-22 ラボラトリオ デ アプリカシオネス ファルマコディナミカス，エセ．アー． イブプロフェンリシナートの経口投与用の懸濁液
ES2347754B1 (es) * 2009-04-27 2011-09-29 Laboratorios De Aplicaciones Farmacodinamicas, S.A Suspension oral de lisinato de ibuprofeno.
ES2347754A1 (es) * 2009-04-27 2010-11-03 Laboratorios De Aplicaciones Farmacodinamicas, S.A Suspension oral de lisinato de ibuprofeno.
WO2012080718A1 (fr) * 2010-12-15 2012-06-21 Reckitt Benckiser Healthcare International Limited Nouvelle formule pharmaceutique contenant un ains et de la cyclodextrine
GB2486567B (en) * 2010-12-15 2014-09-10 Reckitt Benckiser Healthcare Int Ltd Pharmaceutical formulation
GB2486567A (en) * 2010-12-15 2012-06-20 Reckitt Benckiser Healthcare Int Ltd Solutions of an NSAID and one or more cyclodextrins
US9138482B2 (en) 2010-12-15 2015-09-22 Reckitt Benckiser Healthcare International Limited Pharmaceutical formulation comprising NSAID and cyclodextrin
RU2607592C2 (ru) * 2010-12-15 2017-01-10 Рекитт Бенкизер Хелскэа Интернэшнл Лимитед Новая фармацевтическая композиция, включающая нпвс и циклодекстрин
US10363316B2 (en) 2010-12-15 2019-07-30 Reckitt Benckiser Healthcare (Uk) Limited Pharmaceutical formulation comprising NSAID and cyclodextrin
WO2019105957A1 (fr) * 2017-11-30 2019-06-06 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Composition liquide stable de kétoprofène, sels et énantiomères de celui-ci

Also Published As

Publication number Publication date
ES2034926T1 (es) 1993-04-16
CA2066731A1 (fr) 1992-01-14
EP0491897A1 (fr) 1992-07-01
IT9020944A0 (it) 1990-07-13
IT9020944A1 (it) 1992-01-13
AU8093591A (en) 1992-02-04
GR930300021T1 (fr) 1993-04-28
IT1243342B (it) 1994-06-10

Similar Documents

Publication Publication Date Title
WO1992000725A1 (fr) Compositions pharmaceutiques liquides de traitement oral presentant une activite anti-inflammatoire
EP0441307B1 (fr) Composition de sirop
KR100439090B1 (ko) 맛은폐성액체
US5284657A (en) Compositions and methods for the sublingual or buccal administration of therapeutic agents
CA1234050A (fr) Solution injectable pour le traitement des inflammations
EP0444492B1 (fr) Compositions pour l'administration topique à base d'acide hyaluronique de haut poids moléculaire pour traiter les inflammations de la cavité buccale, pour l'hygiène de la cavité buccale et comme traitement cosmétique
JPH05504783A (ja) 水溶解性の高いシクロデキストリン誘導体組成物及びその用途
PT1998762E (pt) Forma farmacêutica sólida contendo um agente activo de sabor mascarado
AU2002306329B2 (en) Aqueous cilostazol preparation for injection
JP2002510652A5 (fr)
JPH0257049B2 (fr)
EP0633787B1 (fr) Utilisation du complexe ibuprofen-beta-cyclodextrine pour l'administration orale
HUP0500842A2 (hu) Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra
EP1974751A1 (fr) Formulations pour médicaments anti-inflammatoires sans stéroïdes
PT1609481E (pt) Composições farmacêuticas injectáveis compreendendo diclofenaco de sódio de beta-ciclodextrina e um polissorbato
AU2003232480B2 (en) Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
JPH0616547A (ja) 消炎点眼剤
EP0867181A1 (fr) Composition nasale de mélatonine
JPH035438A (ja) フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤
TR201909422T4 (tr) Flurbiprofen ve dekspantenolün oral topikal sulu farmasötik bileşimleri.
CA2259270C (fr) Preparation pharmaceutique contenant du nimesulide pour administration orale
EP1242062B1 (fr) Compositions pharmaceutiques pour l'administration topique dans la cavite buccale de produits anti-inflammatoires non steroides
KR100567131B1 (ko) 쓴맛을 차폐한 아르기닌 함유 이부프로펜 경구투여 액상조성물
KR20040079012A (ko) 아세틸시스테인 함유 경구용 제제
KR100509432B1 (ko) Ｓ(+)-이부프로펜을 함유한 시럽제 조성물 및 그의 제조방법

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MC MG MN MW NO PL RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1991911791

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2066731

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991911791

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991911791

Country of ref document: EP